Combinations and uses thereof

An antibody and sequence technology, applied in the field of combination and its application, can solve problems such as poor prognosis of cancer

Active Publication Date: 2018-04-17
MORFOZIS AG
View PDF34 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] Clearly, despite recent advances in the discovery and development of anticancer agents, many forms of cancer involving CD19-expressing tumors still have a poor prognosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combinations and uses thereof
  • Combinations and uses thereof
  • Combinations and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach

[0069] One aspect of the disclosure is a combination of a CD19 specific antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia. In an embodiment, the combination is synergistic.

[0070] Herein, combinations of exemplified anti-CD19 antibodies and Idelalisib act synergistically in in vitro models associated with CLL. Since CLL is a B cell related disease and CD19 is highly expressed on B cells, the exemplified combinations should have the same mechanism of action and should also be synergistic in the treatment of other B cell related disorders such as NHL and ALL. Thus, combinations of exemplary CD19-specific antibodies and Idelalisib should be effective in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia in humans. Clinical trials will demonstrate the expected efficacy of the exemplary CD19-specific antibody in com...

Embodiment 1

[0094] Example 1: Cytotoxicity against MEC-1 cells using MOR00208 and Idelalisib alone and in combination

[0095] Material

[0096] Cell lines: chronic B-cell leukemia cell line MEC-1 cells (DSMZ#ACC497); mantle cell lymphoma cell line JVM-2 ( CRL-3002); Ramos cells (ATCC No. CRL-1596), a human Burkitt's lymphoma cell; HG-3 (DSMZ #ACC765) and Cll (DSMZ #ACC773) are chronic lymphocytic leukemia cell lines; Su-DHL 6 (DSMZ #ACC572), and U2932 (DSMZ #ACC633) are diffuse large B-cell lymphoma (DLBCL) cell lines; BALL-1 (DSMZ #ACC742) is an acute lymphoblastic leukemia cell line.

[0097] The culture conditions of the used cell lines followed the supplier's information.

[0098] Cell culture medium: Iscove's Modified Dulbecco's medium (IMDM), Invitrogen, catalog number: 31980-048; RPMI1640, Invitrogen, catalog number: 31870-074; GlutaMAX, Invitrogen, catalog number: 35050-38, lot number 1654740; FCS : Sigma Catalog Number: F7524, Lot Number: 111M3396.

[0099] NKs: RPMI16...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia.

Description

technical field [0001] The present disclosure relates to a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia. Background technique [0002] B cells are lymphocytes that play an important role in the humoral immune response. They are produced in the bone marrow of most mammals and comprise 5-15% of the circulating lymphoid pool. The main function of B cells is to produce antibodies against various antigens and is an essential component of the adaptive immune system. [0003] Due to their critical role in regulating the immune system, dysregulation of B cells has been linked to various diseases such as lymphoma and leukemia. These diseases include non-Hodgkin's lymphoma ("NHL"), chronic lymphocytic leukemia ("CLL") and acute lymphoblastic leukemia ("ALL"). [0004] NHL is a heterogeneous malignancy derived from lymphocytes...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(China)
IPC IPC(8): A61K39/395C07K16/28
CPCA61K45/06A61K39/3955A61K31/52A61P35/00A61P35/02A61K2300/00A61K39/395C07K16/2803C07K2317/73A61K39/39558C07D403/12C07D473/16C07K2317/565A61K31/505A61K31/519
InventorJ·恩德尔M·温德尔里奇R·博克斯哈默
OwnerMORFOZIS AG